Alpha 2.0
Login Register
» Articles » PMID: 30574180

Rheumatologists' Knowledge of Contraception, Teratogens, and Pregnancy Risks

Overview
Journal Obstet Med
Specialty Gynecology & Obstetrics
Date 2018 Dec 22
PMID 30574180
Citations 9
Authors
Megan Eb Clowse
Amanda M Eudy
Jessica Revels
Gillian D Sanders
Lisa Criscione-Schreiber
Affiliations
Soon will be listed here.
Abstract

Introduction: Rheumatologists are essential partners in planning and managing pregnancies in women with lupus. Whether they know the essentials of contraceptive and medical treatment in pregnancy, however, is unknown.

Method: Anonymous in-lecture surveys were completed by 270 rheumatologists to assess knowledge of contraceptive effectiveness, emergency contraception, medication teratogenicity, and lupus pregnancy risk assessment.

Results: Rheumatologists knew the high effectiveness of the intrauterine device, but over-estimated the effectiveness of injectable medroxyprogesterone and condoms. Almost all identified methotrexate as a teratogen, but only 69% identified cyclophosphamide and 37% mycophenolate. Most rheumatologists knew that lupus activity in pregnancy is the main predictor of pregnancy outcomes, but underestimated the risks of hypertension and race.

Conclusion: To improve lupus pregnancy planning and management, rheumatologists would benefit from improved knowledge about contraceptive effectiveness, teratogens, and the risks from non-lupus factors for pregnancy complications.

Citing Articles

Risk Assessment and Optimization for Pregnancy in Patients with Rheumatic Diseases.

Kwok A Diagnostics (Basel). 2024; 14(13).

PMID: 39001304 PMC: 11241172. DOI: 10.3390/diagnostics14131414.

Teratogenic medication use associated with favourable odds of contraception counselling in a cohort of women with systemic lupus erythematosus at a large tertiary academic medical centre.

Chandramouli S, Alvarez C, Englund T, Silverstein R, Sheikh S Lupus Sci Med. 2022; 9(1).

PMID: 36418076 PMC: 9685263. DOI: 10.1136/lupus-2022-000823.

Pregnancy Intention Screening in Patients With Systemic Rheumatic Diseases: Pilot Testing a Standardized Assessment Tool.

Pryor K, Albert B, Desai S, Ritter S, Tarter L, Coblyn J ACR Open Rheumatol. 2022; 4(8):682-688.

PMID: 35639495 PMC: 9374050. DOI: 10.1002/acr2.11449.

The importance of pregnancy planning in lupus pregnancies.

Rajendran A, Eudy A, Balevic S, Clowse M Lupus. 2021; 30(5):741-751.

PMID: 33509066 PMC: 8026487. DOI: 10.1177/0961203321989803.

Improving Knowledge of Lactation Compatibility of Antirheumatic Medications Among Providers Who Care for Patients With Rheumatic Disease.

Mills B, Bermas B ACR Open Rheumatol. 2021; 3(1):50-54.

PMID: 33393732 PMC: 7811689. DOI: 10.1002/acr2.11214.

References
1.
Clowse M, Magder L, Witter F, Petri M . The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum. 2005; 52(2):514-21. DOI: 10.1002/art.20864. View
2.
Sifontis N, Coscia L, Constantinescu S, Lavelanet A, Moritz M, Armenti V . Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation. 2007; 82(12):1698-702. DOI: 10.1097/01.tp.0000252683.74584.29. View
3.
Chambers C, Johnson D, Robinson L, Braddock S, Xu R, Lopez-Jimenez J . Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum. 2010; 62(5):1494-503. PMC: 3633589. DOI: 10.1002/art.27358. View
4.
Wei Q, Ouyang Y, Zeng W, Duan L, Ge J, Liao H . Pregnancy complicating systemic lupus erythematosus: a series of 86 cases. Arch Gynecol Obstet. 2010; 284(5):1067-71. DOI: 10.1007/s00404-010-1786-5. View
5.
Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, Shechtman S . Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. 2014; 66(5):1101-10. DOI: 10.1002/art.38368. View